||Saturday, June 29, 2013|
|Location:||Commonwealth Hall, The Boston Seaport Hotel|
|Title:||Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like receptors 7, 8 and 9|
Idera Pharmaceuticals To Present Positive Phase 1 Trial Results On TLR Antagonist IMO-8400 For The Treatment Of Autoimmune Diseases At FOCIS 2013
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.